Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: HIV Clin Trials. 2016 Feb 1;17(2):55–62. doi: 10.1080/15284336.2015.1126424

Table 2. Changes in Biomarkers by Study Arm.

Rosiglitazone + rhGH
n = 20		 Rosiglitazone
n = 15		 rhGH
n = 13		 Double Placebo
n = 15		 p-value*
Biomarker Baseline 12-week 12-wk
change		 Baseline 12-week 12-wk
change		 Baseline 12-week 12-wk
change		 Baseline 12-week 12-wk
change
Adiponectin, ng/ml

Median(IQR)		 n=14 n = 14 n=14 n=12 n=12 n=12 n=9 n=9 n=9 n=12 n=12 n=12
5.2
(3.5,6.6)		 10.4
(7.7,14.2)		 4.7**
(1.5,6.7)		 8.2
(5.8,11.8)		 15.2
(10.0,27.5)		 5.7**
(2.6,19.9)		 7.6
(4.9,8.7)		 7.0
(5.7,9.9)		 -0.1
(-1.5,1.2)		 7.2
(4.9,11.6)		 6.5
(4.6,9.9)		 -0.5
(-1.0,0.2)		 0.0004
hsCRP, mg/ml

Median(IQR)		 n=14 n=14 n=14 n=12 n=12 n=12 n=9 n=9 n=9 n=12 n=12 n=12
2.33
(0.7,4.6)		 0.52
(0.2,1.5)		 -1.42
(-2.1,-0.5)		 3.09
(0.9,8.0)		 1.03
(0.5,2.8)		 -1.18
(-4.8,-0.4)		 1.76
(0.6,7.9)		 0.69
(0.2,1.3)		 -1.53
(-4.5,-0.2)		 3.36
(0.7,7.4)		 0.92
(0.4,3.9)		 -0.37
(-2.9,-0.1)		 0.74
Homocysteine, μmol/ml

Median(IQR)		 n=14 n=14 n=14 n=12 n=12 n=12 n=9 n=9 n=9 n=12 n=12 n=12
10.5
(8.8,11.8)		 11.7
(9.7,13.4)		 1.3
(-0.4,2.1)		 11.5
(9.1,14.3)		 10.2
(9.1,12.6)		 -0.6
(-3.3,0.2)		 11.5
(10.0,13.4)		 10.8
(10.1,11.6)		 -0.9
(-1.1,0.8)		 10.9
(8.1,13.5)		 9.8
(8.5,12.8)		 -0.2
(-1.6,2.5)		 0.15
IL-1-β, pg/ml

Median(IQR)		 n=14 n=14 n=14 n=12 n=12 n=12 n=9 n=9 n=9 n=12 n=12 n=12
0.6
(0.3,1.5)		 0.5
(0.3,1.2)		 0
(-0.6,0.0)		 0.3
(0.3,0.9)		 0.3
(0.3,1.0)		 0
(-0.4,0.5)		 0.8
(0.3,0.9)		 0.8
(0.3,1.0)		 0
(0.0,0.7)		 0.3
(0.3,1.1)		 0.3
(0.3,1.0)		 0
(-0.2,0.3)		 0.54
IL-6, pg/ml

Median(IQR)		 n=14 n=14 n=14 n=12 n=12 n=12 n=9 n=9 n=9 n=12 n=12 n=12
1.1
(0.8,1.7)		 0.9
(0.7,1.5)		 -0.1
(-0.3,0.4)		 1.2
(0.8,2.5)		 0.9
(0.7,1.4)		 -0.03
(-1.0,0.2)		 1.3
(1.0,1.8)		 0.9
(0.6,1.7)		 -0.3
(-0.4,-0.2)		 0.9
(0.8,1.5)		 1.0
(0.6,1.3)		 -0.1
(-0.2,0.1)		 0.43
TnFα, pg/ml

Median(IQR)		 n=14 n=14 n=14 n=12 n=12 n=12 n=9 n=9 n=9 n=12 n=12 n=12
7.4
(6.2,10.1)		 8.0
(6.2,9.9)		 0.6
(-0.7,1.2)		 6.8
(5.3,9.6)		 5.6
(5.3,7.0)		 -0.7
(-2.6,-0.2)		 7.1
(6.7,8.5)		 6.5
(4.5,7.1)		 -1.2
(-2.0,-0.5)		 7.5
(5.9,8.3)		 7.7
(4.5,8.5)		 -0.5
(-0.8,1.0)		 0.26
IFnγ, pg/ml

Median(IQR)		 n=14 n=14 n=14 n=12 n=12 n=12 n=9 n=9 n=9 n=12 n=12 n=12
2.5
(1.6,4.3)		 3.5
(3.0,4.2)		 0.7
(-0.1,1.4)		 3.7
(2.2,7.4)		 3.5
(2.0,6.4)		 -0.5
(-2.2,0.9)		 3.3
(2.5,5.4)		 3.1
(2.7,3.7)		 0.5
(-2.7,0.6)		 3.9
(1.8,5.9)		 3.6
(1.8,5.7)		 0.1
(-1.5,2.0)		 0.62
Fibrinogen, mg/dL

Median(IQR)		 n=15 n=15 n=15 n=10 n=10 n=10 n=11 n=11 n=11 n=12 n=12 n=12
182.0
(146,236)		 197.0
(156,222)		 -4
(-34,38)		 229.0
(168,271)		 206.0
(154,226)		 -20.5
(-87,-2)		 193.0
(184,300)		 223.0
(188,268)		 -1
(-25,30)		 237.0
(176,285)		 210.5
(166.5,249.5)		 -10.5
(-36.5,3.5)		 0.40
PAI-1 antigen, ng/ml

Median(IQR)		 n=15 n=15 n=15 n=8 n=8 n=8 n=10 n=10 n=10 n=13 n=13 n=13
393.2
(72.9, 480.4)		 240.4
(76.6, 474.0)		 10.2
(-197.2, 433.5)		 611.9
(254.7, 890.2)		 434.4
(223.8, 943.9)		 -134.1
(-460.8, 306.7)		 412.6
(373.4, 598.2)		 546.2
(301.2, 822.2)		 38.5
(-14.1, 249.2)		 320.8
(131.4, 582.2)		 477.3
(304.8, 581.4)		 -4.1
(-53.4, 73.0)		 0.56
tPA antigen, ng/ml

Median(IQR)		 n=15 n=15 n=15 n=8 n=8 n=8 n=10 n=10 n=10 n=13 n=13 n=13
9.0
(6.2,11.7)		 5.6
(4.4,8.2)		 -3.5
(-5.6,-1.3)		 9.0
(7.6,14.3)		 7.7
(5.5,13.5)		 -1.1
(-3.7,-0.1)		 11.4
(9.3,11.8)		 10.1
(7.3,11.5)		 -2.1
(-2.2,-0.3)		 13.2
(10.8,14.0)		 11.7
(7.6,14.8)		 0.5
(-3.0,1.2)		 0.10
*

Kruskal-Wallis test

**

p=0.0011 for rosiglitazone + rhGH compared to double placebo group, p=0.0005 for rosiglitazone alone compared to double placebo group after Dunnett-Hsu multiple adjustments